Related Experiment Video
Updated: Jun 9, 2026
11:27
A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn
Published on: April 7, 2023
Hypocalcemia in the newborn
Ashish Jain1, Ramesh Agarwal, M Jeeva Sankar
1Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.
Indian Journal of Pediatrics
|August 26, 2010
Summary
Neonatal hypocalcemia, a common issue, affects high-risk infants. Early onset requires 72-hour calcium treatment, while late onset needs longer therapy.
Area of Science:
- Neonatal Medicine
- Biochemistry
- Pediatrics
Background:
- Hypocalcemia is a frequent clinical and laboratory abnormality in neonates.
- Ionic calcium plays a vital role in blood coagulation, neuromuscular excitability, and cellular functions.
- Healthy term infants experience a physiological drop in serum calcium levels within 24-48 hours of birth.
Purpose of the Study:
- To review the causes, presentation, and management of neonatal hypocalcemia.
- To differentiate between early-onset and late-onset hypocalcemia in neonates.
- To outline treatment strategies for neonatal hypocalcemia.
Main Methods:
- Literature review of neonatal hypocalcemia.
- Analysis of clinical presentation and laboratory findings.
- Summary of current treatment guidelines for calcium supplementation.
Main Results:
- High-risk neonates (e.g., infants of diabetic mothers, preterm infants, those with perinatal asphyxia) are prone to hypocalcemic levels.
- Early-onset hypocalcemia (within 72 hours) necessitates calcium supplementation for at least 72 hours.
- Late-onset hypocalcemia (after 7 days) typically requires extended therapeutic intervention.
Conclusions:
- Prompt diagnosis and appropriate calcium supplementation are critical for managing neonatal hypocalcemia.
- Understanding the timing of onset is key to determining the duration of treatment.
- Effective management of neonatal hypocalcemia is essential for preventing complications.
Related Concept Videos
01:21Skeleton and Calcium Homeostasis
Calcium is not only the most abundant mineral in bone but also the most abundant mineral in the human body. Calcium ions are needed for bone mineralization, tooth health, heart rate regulation and strength of contraction, blood coagulation, the contraction of smooth and skeletal muscle cells, and the regulation of nerve impulse conduction. The average calcium level in the blood is about 10 mg/dL. When the body cannot maintain this level, a person will experience hypo or hypercalcemia.
00:51Synthesis and Functions of Calcitonin
Calcitonin, a vital polypeptide hormone, regulates calcium levels within body fluids. It is released by the parafollicular cells, also known as C cells, situated in the follicular epithelium of the thyroid gland. Calcitonin responds to fluctuations in blood calcium levels and the influence of gastrointestinal hormones like gastrin and cholecystokinin.
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
01:17Hormones and Bone Tissue
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...